他克莫司治疗类风湿关节炎的疗效和安全性。
The efficacy and safety of tacrolimus in rheumatoid arthritis.
出版信息
Ther Adv Musculoskelet Dis. 2011 Dec;3(6):283-91. doi: 10.1177/1759720X11419038.
Abstract
The crucial role of T cells in the pathogenesis of rheumatoid arthritis (RA) is well recognized. Tacrolimus is an immunomodulator that acts by the inhibition of T-cell activation. There have been numerous studies examining the use of tacrolimus in RA, including four randomized controlled trials. This article reviews these data with respect to the efficacy of the use of tacrolimus in RA as monotherapy and as part of combination therapy. The safety of tacrolimus use in RA is then evaluated. Tacrolimus is shown to be an effective and safe therapeutic option for RA patients intolerant of or resistant to previous disease-modifying antirheumatic drugs (DMARDs). In addition to monotherapy, tacrolimus has been successfully used as part of combination RA therapy, in particular in conjunction with methotrexate. Further assessment of combination approaches involving tacrolimus use alongside other DMARDs or biologics would be helpful. More studies are required to examine the effects of tacrolimus on the radiographic progression of RA.
摘要
T 细胞在类风湿关节炎（RA）发病机制中的关键作用已得到充分认识。他克莫司是一种免疫调节剂，通过抑制 T 细胞活化起作用。已经有许多研究检查了他克莫司在 RA 中的应用，包括四项随机对照试验。本文回顾了这些数据，以评估他克莫司作为单药治疗和联合治疗在 RA 中的疗效。然后评估了他克莫司在 RA 中的使用安全性。他克莫司是一种对先前的疾病修饰抗风湿药物（DMARDs）不耐受或耐药的 RA 患者有效的安全治疗选择。除了单药治疗外，他克莫司已成功用于联合 RA 治疗，特别是与甲氨蝶呤联合使用。进一步评估包括他克莫司与其他 DMARDs 或生物制剂联合使用的联合方法将是有益的。需要更多的研究来检查他克莫司对 RA 放射学进展的影响。
相似文献
1
The efficacy and safety of tacrolimus in rheumatoid arthritis.他克莫司治疗类风湿关节炎的疗效和安全性。
Ther Adv Musculoskelet Dis. 2011 Dec;3(6):283-91. doi: 10.1177/1759720X11419038.
2
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.阿达木单抗、依那西普和英夫利昔单抗治疗成人类风湿关节炎有效性的系统评价及其成本效益的经济学评估。
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420.
3
Tacrolimus: in patients with rheumatoid arthritis.他克莫司：用于类风湿关节炎患者。
Drugs. 2005;65(7):993-1001; discussion 1002-3. doi: 10.2165/00003495-200565070-00005.
4
[Effect of disease modifying anti-rheumatic drugs on radiographic progression in rheumatoid arthritis].[改善病情抗风湿药对类风湿关节炎影像学进展的影响]
Clin Calcium. 2009 Mar;19(3):395-403.
5
Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.托法替布治疗疾病修饰抗风湿药物治疗失败后的类风湿关节炎：NICE 单技术评估的循证评价组观点。
Pharmacoeconomics. 2018 Sep;36(9):1063-1072. doi: 10.1007/s40273-018-0639-0.
6
Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.环孢素和他克莫司用于治疗类风湿关节炎。
Curr Opin Rheumatol. 2007 May;19(3):238-45. doi: 10.1097/BOR.0b013e328099af80.
7
Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.他克莫司在甲氨蝶呤治疗失败的类风湿关节炎患者中的疗效：一项为期6个月的双盲、随机、剂量范围研究。
Arthritis Rheum. 2002 Aug;46(8):2020-8. doi: 10.1002/art.10427.
8
Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.他克莫司治疗活动期类风湿关节炎的系统评价和荟萃分析：随机对照试验。
Scand J Rheumatol. 2010 Aug;39(4):271-8. doi: 10.3109/03009740903501642.
9
Efficacy and safety of tacrolimus treatment for rheumatoid arthritis patients undergoing hemodialysis.他克莫司治疗接受血液透析的类风湿关节炎患者的疗效与安全性。
Mod Rheumatol. 2008;18(3):296-300. doi: 10.1007/s10165-008-0044-1. Epub 2008 Mar 6.
10
Efficacy of tacrolimus in infliximab-refractory progressive rheumatoid arthritis.他克莫司在英夫利昔单抗难治性进展性类风湿关节炎中的疗效。
Rheumatol Int. 2009 Feb;29(4):459-61. doi: 10.1007/s00296-008-0694-5. Epub 2008 Sep 18.
引用本文的文献
1
A randomized controlled trial comparing tacrolimus versus hydrocortisone for the treatment of atopic dermatitis in children: new perspectives on interferon gamma-induced protein and growth-related oncogene-α.一项比较他克莫司与氢化可的松治疗儿童特应性皮炎的随机对照试验：关于γ-干扰素诱导蛋白和生长相关癌基因-α的新观点
Front Med (Lausanne). 2024 Jul 24;11:1399305. doi: 10.3389/fmed.2024.1399305. eCollection 2024.
2
2023 Management Recommendations of Bangladesh Rheumatology Society on Pharmacological Treatment of Rheumatoid Arthritis With Synthetic and Biologic Disease-Modifying Drugs.2023年孟加拉国风湿病学会关于使用合成和生物改善病情药物治疗类风湿关节炎的管理建议。
Cureus. 2024 Apr 30;16(4):e59395. doi: 10.7759/cureus.59395. eCollection 2024 Apr.
3
Potential profound fluctuation in tacrolimus concentration on consumption of pomegranate rind extract: A Pharmacokinetic Experiment.食用石榴皮提取物后他克莫司浓度可能出现的显著波动：一项药代动力学实验。
Front Pharmacol. 2023 Apr 19;14:1140706. doi: 10.3389/fphar.2023.1140706. eCollection 2023.
4
Endoplasmic Reticulum Stress, Oxidative Stress, and Rheumatic Diseases.内质网应激、氧化应激与风湿性疾病
Antioxidants (Basel). 2022 Jun 29;11(7):1306. doi: 10.3390/antiox11071306.
5
Risk of New-Onset Diabetes Mellitus Associated with Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study.类风湿关节炎患者中抗风湿药物与新发糖尿病的关联风险：一项全国性人群研究
J Clin Med. 2022 Apr 10;11(8):2109. doi: 10.3390/jcm11082109.
6
Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies.自身免疫性风湿病中的脂质代谢：对现代和传统治疗的影响。
J Clin Invest. 2022 Jan 18;132(2). doi: 10.1172/JCI148552.
7
Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis.他克莫司作为单一药物免疫治疗和非胸腺瘤重症肌无力的轻微表现状态。
J Immunol Res. 2021 Nov 20;2021:9138548. doi: 10.1155/2021/9138548. eCollection 2021.
8
Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases.药物再利用以改善风湿免疫性炎症性疾病的治疗。
Nat Rev Rheumatol. 2020 Jan;16(1):32-52. doi: 10.1038/s41584-019-0337-0. Epub 2019 Dec 12.
9
Anti-receptor activator of nuclear factor κB ligand antibody treatment increases osteoclastogenesis-promoting IL-8 in patients with rheumatoid arthritis.抗核因子 κB 配体受体抗体治疗可增加类风湿关节炎患者促进破骨细胞形成的白细胞介素-8。
Int Immunol. 2019 Apr 26;31(5):277-285. doi: 10.1093/intimm/dxz009.
10
Neutropenia in the Elderly: A Rheumatology Perspective.老年人中性粒细胞减少症：风湿病学视角
Drugs Aging. 2016 Aug;33(8):585-601. doi: 10.1007/s40266-016-0383-0.
本文引用的文献
1
Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.他克莫司治疗活动期类风湿关节炎的系统评价和荟萃分析：随机对照试验。
Scand J Rheumatol. 2010 Aug;39(4):271-8. doi: 10.3109/03009740903501642.
2
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.EULAR 推荐的使用合成和生物疾病修饰抗风湿药物治疗类风湿关节炎的建议。
Ann Rheum Dis. 2010 Jun;69(6):964-75. doi: 10.1136/ard.2009.126532. Epub 2010 May 5.
3
Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis.他克莫司，一种钙调磷酸酶抑制剂，克服了难治性类风湿关节炎中淋巴细胞 P 糖蛋白介导的治疗无反应性。
J Rheumatol. 2010 Mar;37(3):512-20. doi: 10.3899/jrheum.090048. Epub 2010 Jan 15.
4
Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies.在对肿瘤坏死因子抑制剂治疗反应不足的类风湿性关节炎患者中添加低剂量他克莫司。
Rheumatol Int. 2009 Sep;29(11):1287-91. doi: 10.1007/s00296-009-0845-3. Epub 2009 Jan 20.
5
Safety of long-term tacrolimus therapy for rheumatoid arthritis: an open-label, uncontrolled study in non-elderly patients.类风湿关节炎长期使用他克莫司治疗的安全性：一项针对非老年患者的开放标签、非对照研究。
Mod Rheumatol. 2008;18(4):345-53. doi: 10.1007/s10165-008-0058-8. Epub 2008 Apr 22.
6
Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis.克服难治性类风湿关节炎患者淋巴细胞上P-糖蛋白诱导的耐药性。
Ann Rheum Dis. 2008 Mar;67(3):380-8. doi: 10.1136/ard.2007.070821. Epub 2007 Jul 27.
7
Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis.他克莫司与咪唑立宾在类风湿关节炎患者中的随机双盲对照研究比较。
J Rheumatol. 2006 Nov;33(11):2153-61. Epub 2006 Sep 1.
8
Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients.免疫抑制剂他克莫司治疗老年类风湿关节炎的安全性。
Rheumatology (Oxford). 2006 Apr;45(4):441-4. doi: 10.1093/rheumatology/kei172. Epub 2005 Nov 1.
9
FK506 inhibits prostaglandin E2 production from synovial cells by suppressing peripheral blood mononuclear cells.FK506通过抑制外周血单核细胞来抑制滑膜细胞产生前列腺素E2。
Int Immunopharmacol. 2005 Jul;5(7-8):1291-7. doi: 10.1016/j.intimp.2005.03.014. Epub 2005 Apr 21.
10
FK506 suppresses the stimulation of matrix metalloproteinase 13 synthesis by interleukin-1beta in rheumatoid synovial fibroblasts.他克莫司抑制类风湿性滑膜成纤维细胞中白细胞介素-1β对基质金属蛋白酶13合成的刺激作用。
Immunol Lett. 2005 May 15;98(2):194-9. doi: 10.1016/j.imlet.2004.11.014. Epub 2004 Dec 9.
Zotero 插件